Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560
Debt
Debt-to-Equity RatioN/A
Current Ratio11.37
Quick Ratio11.27
Price-To-Earnings
Trailing P/E Ratio-10.82
Forward P/E Ratio-22.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.07 million
Price / Sales255.81
Cash FlowN/A
Price / CashN/A
Book Value$13.88 per share
Price / Book5.95
Profitability
EPS (Most Recent Fiscal Year)($7.63)
Net Income$-253,480,000.00
Net Margins-935.38%
Return on Equity-51.76%
Return on Assets-42.28%
Miscellaneous
Employees315
Outstanding Shares37,390,000
Market Cap$3,176.69
Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics Inc (NASDAQ:ONCE) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.80. The biotechnology company earned $15.68 million during the quarter, compared to analyst estimates of $51.55 million. Spark Therapeutics had a negative net margin of 935.38% and a negative return on equity of 51.76%. The business's revenue for the quarter was up 1134.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.70) earnings per share. View Spark Therapeutics' Earnings History.
What price target have analysts set for ONCE?
22 brokers have issued 1 year price targets for Spark Therapeutics' shares. Their predictions range from $40.00 to $113.00. On average, they anticipate Spark Therapeutics' stock price to reach $78.0476 in the next twelve months. This suggests that the stock has a possible downside of 5.5%. View Analyst Ratings for Spark Therapeutics.
What is the consensus analysts' recommendation for Spark Therapeutics?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
- 1. Raymond James analysts commented, "We are maintaining our Outperform rating for Spark. Hemophilia (WFH) 2018 World Congress, the company, along with its partner, Pfizer, provided an update on the ongoing Phase I/II study evaluating SPK-9001 for hemophilia B (Hem B). In addition, Spark’s competitor, BioMarin, provided an update on the ongoing Phase I/II trial of valoctocogene roxaparvovec (or BMN 270) in severe hemophilia A (Hem A)." (5/23/2018)
- 2. Mizuho analysts commented, "We expect the update to be an important catalyst given the large market opportunity in this indication. We expect to see data from three-dose cohorts and a longer follow-up time since the last update at the Hematology (ASH) in December 2017. Management is also advancing preparations for a phase 3 trial in parallel." (5/8/2018)
- 3. Cantor Fitzgerald analysts commented, "Updates to our Model. We are increasing our PT to $103/share from $100, based on the adjustment to our estimate of 2018 YE net cash. This increase is driven by a year-end cash increase from $549 million to $659 million ($18/ share), which accounts for the $110 million increase (a $3/share increase)." (4/30/2018)
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA).
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the folowing people:
- Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 39)
- Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 66)
- Mr. Stephen W. Webster, Chief Financial Officer (Age 57)
- Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 47)
- Mr. Daniel R. Faga, Chief Bus. Officer (Age 38)
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.
Has Spark Therapeutics been receiving favorable news coverage?
Media stories about ONCE stock have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.09 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Spark Therapeutics' major shareholders?
Spark Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Columbia Partners L L C Investment Management (0.04%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.
Which major investors are selling Spark Therapeutics stock?
ONCE stock was sold by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management. Company insiders that have sold Spark Therapeutics company stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.
How do I buy shares of Spark Therapeutics?
Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spark Therapeutics' stock price today?
One share of ONCE stock can currently be purchased for approximately $82.58.
How big of a company is Spark Therapeutics?
Spark Therapeutics has a market capitalization of $3.18 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.
How can I contact Spark Therapeutics?
Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]
MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
